Neptune Technologies & Bioresources, Inc. announced unaudited consolidated earnings results for the third quarter and nine months ended November 30, 2009. For the quarter, the company reported revenue from sales and research contracts of CAD 3,758,243 and loss before special items of CAD 75,431 compared to revenue from sales and research contracts of CAD 2,451,322 and loss before special items of CAD 1,774,052 for the same period last year. The company reported net income of CAD 2,022,865 or CAD 0.050 diluted per share compared to net loss of CAD 1,359,756 or CAD 0.036 diluted losses per share for the same period last year. The company reported net cash used in operating activities of CAD 934,360, additions to property, plant and equipment of CAD 237,609 and additions to intangible assets of CAD 4,091 compared to net cash used in operating activities of CAD 10,068, additions to property, plant and equipment of CAD 356,667 and additions to intangible assets of CAD 55,334 for the same period last year. For the nine months, the company reported revenue from sales and research contracts of CAD 8,006,560 and loss before special items of CAD 2,996,842 compared to revenue from sales and research contracts of CAD 7,951,214 and loss before special items of CAD 3,992,490 for the same period last year. The company reported net loss of CAD 1,495,814 or CAD 0.040 diluted losses per share compared to net loss of CAD 3,239,915 or CAD 0.086 diluted loss per share for the same period last year. The company reported net cash used in operating activities of CAD 1,472,982, additions to property, plant and equipment of CAD 3,230,975 and additions to intangible assets of CAD 145,722 compared to net cash used in operating activities of CAD 585,501, additions to property, plant and equipment of CAD 369,015 and additions to intangible assets of CAD 531,258 for the same period last year.

Neptune Technologies & Bioresources, Inc. announced consolidated earnings results for the third quarter and nine months ended November 30, 2009. For the quarter, the company reported Nutraceutical business revenue amounted to $3,756,000 compared to $2,411,000 same period ended November 30, 2008, representing 56% increases. EBITDA of Neptune nutraceutical business for the quarter amounted to a $874,000 compared to a negative $389,000 for the same period last year. Comprehensive net income or net loss attributable to Neptune nutraceutical business for quarter amounted to a net income of $2,462,000 compared to losses of $1,039,000 for the period ended November 30, 2008. Excluding $2,142,000 gain on dilution from debenture conversion, comprehensive net income or loss for the period amounted to an income of $320,000. For the nine months, the company reported Nutraceutical business revenue amounted to $7,966,000 compared to $7,871,000 same period ended November 30, 2008, representing 1% increases. EBITDA of Neptune nutraceutical business for the period amounted to a negative $87,000 compared to positive $260,000 for the same period last year. Comprehensive net income or net loss attributable to Neptune nutraceutical business for the nine months amounted to net loss of $92,000 compared to losses of $2,696,000 for the period ended November 30, 2008. Excluding $2,142,000 gain on dilution from debenture conversion, comprehensive net income or loss for the period amounted to loss of $2,234,000. For the quarter of Neptune, Acasti and Neurobiopharm consolidated financial results, the company reported total revenue amounted to $3,758,000 compared to $2,451,000 same period ended November 30, 2008, representing increases of 53%. EBITDA for the three months periods ended November 30, 2009 amounted to a positive $440,000 compared to a negative $709,000 for the same period last year. Comprehensive net income for the quarter amounted to a net income of $2,023,000 compared to losses of $1,360,000 for the same period last year. Excluding $2,142,000 gain on dilution from debenture conversion, comprehensive net loss for the quarter amounted to $119,000. For the nine months of Neptune, Acasti and Neurobiopharm consolidated financial results, the company reported revenue amounted to $8,007,000, compared to $7,951,000 for the nine-month periods ended November 30, 2008, representing respectively increases of 1%. EBITDA for the nine-month periods ended November 30, 2009 amounted to a negative $1,478,000, compared to a negative $282,000 for the nine-month periods ended November 30, 2008. Comprehensive net income or net loss for the nine-month periods ended November 30, 2009, amounted to net loss of $1,496,000 compared to $3,240,000 for the nine-month periods ended November 30, 2008. Excluding $2,142,000 gain on dilution from debenture conversion, comprehensive net loss for the nine-month periods ended November 30, 2009 respectively amounted to $3,638,000.

Neptune Technologies & Bioresources, Inc. announced additional preclinical research results on its Acasti Pharma Inc. drug development program. Acasti announced the results of additional preclinical research designed to further evaluate the potentially broader spectrum of therapeutic efficacy of its first drug candidate, _CaPreTM_. The efficacy of _CaPreTM_ was evaluated in the same animal model, the Zucker Diabetic Fatty model, with which, as previously reported, _CaPreTM_ demonstrated significant anti-dyslipidemic effects associated with substantial elevations of High-density lipoprotein-Cholesterol ("HDL-C") or "good cholesterol". CaPreTM_ was administered for 3 months at a daily human equivalent dose of 500mg and 2,500mg in both ZDF diabetic (established, severe, type 2 diabetes) and normal healthy rats. Both rat phenotypes were subjected to oral glucose tolerance tests. In medical practice the OGTT is commonly used to test for diabetes and insulin resistance. It involves the oral administration of high amounts of glucose in order determine how quickly it is cleared from the blood. The test may be performed as part of a panel of tests, such as the comprehensive metabolic panel.

Neptune Krill Oil Tests Below Strictest Detection Limits for PCB and Recognized as a Target of Excellence by Industry Peers and Competitors

Neptune Krill Oil Tests Below Strictest Detection Limits for PCB and Recognized as a Target of Excellence by Industry Peers and Competitors

Neptune Technologies & Bioressources Inc. Provides a Corporate and Operations Update

Neptune Technologies & Bioressources Inc. is Granted Method of Use Patent for Cardiovascular Disease Applications in Europe; EFSA Stamps Final Approval for NKO(R) NOVEL FOOD and PARNUTS Status

Neptune Technologies & Bioressources Reports Second Quarter Results and Production Update

Neptune Technologies & Bioressources Inc. Reports on Active Pharmaceutical Ingredient (API) Preclinical Research; Significant HDL Increase Confirmed

Neptune Technologies & Bioressources Inc. Reports on Active Pharmaceutical Ingredient (API) Preclinical Research; Significant Anti-dyslipidemic Effects Confirmed

Neptune Reports Third Quarter Sales Estimate and Business Update

Neptune Technologies & Bioressources Inc. Reports on Medical Food Candidate Preclinical Research; Pilot ADHD Effect is Confirmed

Neptune Technologies & Bioressources Inc. Has Filed a Patent Infringement Lawsuit Against Aker Biomarine ASA, Jedwards International Inc. and Virgin Antarctic LLC

Neptune Technologies & Bioressources Reports Third Quarter Results

Neptune Technologies & Bioressources Reports on Additional Preclinical Research Results of Drug Candidate CaPre(TM) Improvement of Glucose Tolerance

Neptune Technologies & Bioressources Reports Third Quarter Results

Neptune Technologies & Bioressources Reports on Additional Preclinical Research Results of Drug Candidate CaPre(TM) Improvement of Glucose Tolerance

Neptune Reports Third Quarter Sales Estimate and Business Update

Neptune Technologies & Bioressources Inc. Has Filed a Patent Infringement Lawsuit Against Aker Biomarine ASA, Jedwards International Inc. and Virgin Antarctic LLC

Neptune Technologies & Bioressources Reports Second Quarter Results and Production Update

Neptune Technologies & Bioressources Inc. to Present At the Canaccord Adams Healthy Living Conference On September 23, 2009

Neptune Technologies & Bioressources Inc. Provides a Corporate and Operations Update

Neptune Technologies & Bioressources Inc. is Granted Method of Use Patent for Cardiovascular Disease Applications in Europe; EFSA Stamps Final Approval for NKO(R) NOVEL FOOD and PARNUTS Status